The present invention relates to a pharmaceutical combination for the treatment of schizophrenia and acute manic episodes associated with bipolar disorders, comprising a compound which is active on a trace amine-associated receptor 1 (TAAR1 agonist) and an antipsychotic drug. It has surprisingly been found that such a combination can reduce metabolic side effects which appear if using an antipsychotic drug alone.